Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Drug analysis

Drug analysis


  • Sort by Random
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 45 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Ganetespib

    Read More

    Ganetespib, under development by Synta, is a small molecule inhibitor of HSP90. HSP90 is a chaperone protein required to drive growth, proliferation, and cell survival in tumor tissue.

    September 17, 2015
    Find out more
  • Tivicay

    Read More

    Tivicay (dolutegravir; ViiV Healthcare) is a once-daily, unboosted integrase inhibitor (INI) for the treatment of HIV-1 infection.

    June 28, 2019
    Find out more
  • Visudyne

    Read More

    Visudyne (verteporfin; Valeant/Novartis) is a benzoporphyrin derivative photosensitizer developed for

    use in photodynamic therapy.

    April 4, 2016
    Find out more
  • Toca 511/FC

    Read More

    Toca 511 (vocimagene amiretrorepvec) and Toca FC (5-fluorocytosine) are under investigation as a
    combination therapy for use in recurrent high-grade gliomas, including GBM. Toca 511 is an
    injectable retroviral replicating vector that encodes the prodrug activator enzyme cytosine deaminase
    (CD), which is derived from yeast and not found in the human genome

    April 13, 2016
    Find out more
  • Viekira Pak franchise

    Read More

    AbbVie’s Viekira Pak franchise comprises Viekira Pak ([paritaprevir + ritonavir + ombitasvir] + dasabuvir), Viekira XR ([paritaprevir + ritonavir + ombitasvir + dasabuvir]), and Technivie ([paritaprevir + ritonavir + ombitasvir]), which is branded as Viekirax outside the US market.

    November 6, 2017
    Find out more
  • Tenelia

    Read More

    Tenelia (teneligliptin; Mitsubishi Tanabe) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class. DPP-IV is an enzyme responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1 (GLP-1), which is released postprandially from the gut.

    November 7, 2017
    Find out more
  • Sutent

    Read More

    Sutent (sunitinib; Pfizer) is an orally available multi-targeted tyrosine kinase inhibitor which specifically inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-KIT, and FLT3.

    March 6, 2019
    Find out more
  • Tivantinib

    Read More

    Tivantinib (ArQule/Daiichi Sankyo/Kyowa Hakko Kirin) is an orally available small molecule inhibitor of the hepatocyte growth factor (HGF) receptor, c-MET.

    December 31, 2015
    Find out more
  • ALKS 3831

    Read More

    ALKS 3831 is an orally available, fixed-dose combination of samidorphan (ALKS 33) and olanzapine being developed by Alkermes.

    April 9, 2018
    Find out more
  • Kymriah

    Read More

    Kymriah (tisagenlecleucel; Novartis) is a cluster of differentiation (CD)19-targeted genetically modified autologous T-cell immunotherapy, comprised of a murine single-chain antibody fragment that binds CD19 and is linked to intracellular signaling domains from 4-1BB (CD137) and CD3 zeta.

    January 31, 2019
    Find out more
  • Delafloxacin

    Read More

    Delafloxacin is a novel broad-spectrum fluoroquinolone that prevents bacterial DNA synthesis through its equal inhibitory effect against the enzymes topoisomerase II (DNA gyrase) and IV.

    September 10, 2014
    Find out more
  • LR769

    Read More

    LR769 is a recombinant factor VIIa (rfVIIa) therapy in development by LFB for patients with hemophilia A or B with inhibitors.

    May 4, 2018
    Find out more
  • ND0612_172024

    ND0612

    Read More

    The ND0612 (Mitsubishi Tanabe) product line comprises two subcutaneous, continuously delivered carbidopa/levodopa liquid formulations: the lower-dose ND0612L, and the higher-dose ND0612H.

    June 21, 2018
    Find out more
  • VK2809

    Read More

    VK2809 (Viking Therapeutics) is a thyroid hormone receptor (THR) β-selective agonist which is selective to liver tissue. It is delivered as a prodrug. VK2809 selectively activates the cytochrome P450 isozyme 3A4 (CYP3A4), which is predominantly found in the liver. This allows increased hepatic exposure, which simultaneously reduces systemic exposure to other tissues such as skeletal muscle and the heart.

    July 22, 2019
    Find out more
  • Zeltherva

    Read More

    Zeltherva’s (galinpepimut-S; SELLAS Life Sciences Group) larger target patient population gives it more commercial potential than other drugs being positioned towards the maintenance setting.

    July 6, 2017
    Find out more
  • Torisel

    Read More

    Torisel (temsirolimus; Pfizer) is an inhibitor of mammalian target of rapamycin (mTOR), which is an intracellular protein that has been implicated in multiple growth-related cellular functions.

    March 6, 2019
    Find out more
  • aspirin

    Aspirin

    Read More

    Aspirin (acetylsalicylic acid) is a non-steroidal anti-inflammatory drug (NSAID) and antiplatelet that is taken orally and commonly used for the treatment of pain. It is highly genericized and has been available in its present form since 1899, when it was first marketed by Bayer.

    July 2, 2018
    Find out more
  • Lidoderm

    Read More

    Lidoderm is a medicated plaster containing 5% lidocaine, and was developed by Endo Pharmaceuticals. Lidocaine is an amide-type local anesthetic agent that acts by stabilizing neuronal membranes.

    May 31, 2018
    Find out more
  • Ibrance

    Read More

    Ibrance (palbociclib; Pfizer) is a small-molecule inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6). When associated with cyclin-D proteins, CDK4/6 are able to phosphorylate and inactivate.

    February 4, 2016
    Find out more
  • Rapastinel

    Read More

    Rapastinel is a synthetic tetrapeptide, comprising of threonine–proline–proline–threonine, that acts as a partial agonist at the glycine site of the N-methyl-D-aspartate (NMDA) receptor.

    March 29, 2019
    Find out more
  • alks_5461 report

    ALKS 5461

    Read More

    ALKS 5461 (Alkermes) is a fixed-dose combination of buprenorphine, a mu opioid receptor partial agonist and kappa opioid receptor antagonist, and samidorphan (ALKS 33), which is a proprietary opioid modulator.

    March 29, 2019
    Find out more
  • Idalopirdine

    Read More

    Idalopirdine (Lundbeck/Otsuka) is an active, potent, and selective oral 5-hydroxytryptamine-6 receptor antagonist.

    September 2, 2016
    Find out more
  • MenQuadfi

    Read More

    Sanofi’s MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) is a second-generation active polyvalent conjugate vaccine against group A, C, Y, and W meningococcal infection. It is presented as a sterile solution for injection containing Neisseria meningitidis capsular polysaccharide antigens individually conjugated to tetanus toxoid protein.

    September 3, 2019
    Find out more
  • Lumateperone

    Read More

    Lumateperone is a novel, orally available antipsychotic being developed by Intra-Cellular Therapies for several neuropsychiatric disorders.

    April 9, 2018
    Find out more
  • Incruse

    Incruse

    Read More

    Incruse (umeclidinium; GlaxoSmithKline) is a once-daily long-acting muscarinic antagonist (LAMA) indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

    July 31, 2018
    Find out more
  • Zontivity

    Read More

    Zontivity (vorapaxar; Merck & Co) gained US and EU approval for the reduction of thromboembolic

    events in secondary-prevention patients with a history of myocardial infarction (MI).

    April 14, 2016
    Find out more
  • Xofigo

    Read More

    Xofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly localized short-range alpha irradiation. The drug acts as a calcium mimic and is taken up in the areas of increased bone metabolism, which are associated with bone metastases.

    January 18, 2018
    Find out more
  • Sorilux

    Read More

    Following its 2010 launch, Sorilux (calcipotriene; Stiefel/GlaxoSmithKline) has experienced slow

    uptake in the psoriasis market, despite having the financial support of GlaxoSmithKline. This comes as

    no surprise as the US psoriasis market is saturated with several types of established calcipotriene

    formulations, limiting Sorilux’s uptake.

    August 26, 2016
    Find out more
  • cyramza thumbnail

    Cyramza

    Read More

    Cyramza (ramucirumab; Eli Lilly/Shire) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature.

    September 9, 2019
    Find out more
  • Quizartinib

    Read More

    Quizartinib (Daiichi Sankyo) is an oral multi-tyrosine kinase inhibitor of the platelet-derived growth factor receptor, KIT/c-KIT, and FMS-like tyrosine kinase 3 (FLT3) receptor.

    July 6, 2017
    Find out more
  • Ongentys

    Ongentys

    Read More

    Ongentys (Neurocrine/Bial/Ono Pharmaceutical) is a once-daily formulation of the catechol-O-methyltransferase (COMT) inhibitor opicapone, approved as an add-on therapy to levodopa for the treatment of Parkinson’s disease patients with end-of-dose motor fluctuations.

    June 21, 2018
    Find out more
  • LixiLan

    Read More

    LixiLan is a once-daily, injectable combination product comprising a fixed ration of Sanofi’s long-lasting basal insulin, Lantus, and glucagon-like peptide-1 (GLP-1) receptor agonist, Lyxumia (lixisenatide).

    June 23, 2016
    Find out more
  • APL-130277

    APL-130277

    Read More

    APL-130277 (Dainippon Sumitomo/Sunovion)  is a sublingual film formulation of apomorphine, a non-ergoline dopamine receptor agonist.

    June 21, 2018
    Find out more
  • adagloxad simolenin

    Read More

    Adagloxad simolenin (OBI Pharma) is a carbohydrate-based vaccine comprised of Globo-H conjugated to keyhole limpet hemocyanin. Upon exposure to the synthetic Globo-H vaccine and an immunological adjuvant, the immune system mounts IgM and IgG responses against Globo-H hexasaccharide.

    February 26, 2020
    Find out more
  • Bexsero

    Read More

    Bexsero (multicomponent meningococcal serogroup B vaccine; GlaxoSmithKline) is a multicomponent meningococcal serogroup B vaccine. It is approved for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in adolescents and young adults from 10 years through to 25 years of age in the US, and in individuals two months of age and older in the EU. Bexsero contains three surface-exposed recombinant proteins: factor H binding protein, Neisseria adhesin A, and Neisseria heparin-binding antigen. It also includes New Zealand strain outer membrane vesicles. The antibodies generated after immunization with Bexsero target the aforementioned surface proteins present on the outer membrane vesicles.

    September 3, 2019
    Find out more
  • Geodon

    Read More

    Geodon contains ziprasidone, a dopamine (D2) and serotonin (5-HT2) antagonist developed and marketed by Pfizer.

    April 9, 2018
    Find out more
  • Zepsyre

    Read More

    Zepsyre (lurbinectedin; PharmaMar/Chugai) is a novel synthetic agent derived from the marine-derived alkaloid trabectedin that inhibits the transcription process.

    August 17, 2017
    Find out more
  • Alimta

    Read More

    Alimta is an antifolate antineoplastic agent that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication.

    August 30, 2018
    Find out more
  • gocorvi

    Gocovri

    Read More

    Gocovri (Adamas Pharmaceuticals) is an extended-release formulation of amantadine, uniquely indicated for the treatment of levodopa-induced dyskinesia (LID) in Parkinson’s disease.

    June 21, 2018
    Find out more
  • Aubagio

    Read More

    Aubagio is the major active metabolite of Arava (leflunomide), Sanofi’s oral treatment for rheumatoid arthritis, and is a dihydroorotate dehydrogenase (DHODH) inhibitor.

    November 24, 2017
    Find out more
  • Atripla

    Read More

    Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection.

    June 28, 2019
    Find out more
  • Plavix

    Read More

    Plavix is an antiplatelet agent that inhibits blood clot formation. It works by irreversibly binding to the blood platelet’s adenosine diphosphate (ADP) P2Y12 receptor, preventing ADP-mediated activation of the glycoprotein IIb/IIIa complex.

    July 2, 2018
    Find out more
  • Repatha

    Repatha

    Read More

    Repatha (evolocumab; Amgen/Astellas) is a fully human monoclonal immunoglobulin G2 antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).

    November 20, 2019
    Find out more
  • Coumadin

    Read More

    Coumadin is an orally available vitamin K antagonist (VKA) indicated for the prophylaxis and

    treatment of deep vein thrombosis and pulmonary embolism.

    August 2, 2016
    Find out more
  • Aggrenox

    Aggrenox

    Read More

    Aggrenox (Boehringer Ingelheim/GlaxoSmithKline/Bayer) capsules contain two active ingredients, acetylsalicylic acid and extend-release dipyridamole.

    July 2, 2018
    Find out more
Page 3 of 14
Page 3 of 14‹12345›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top